Core Viewpoint - China Regenerative Medicine International Limited has announced a debt repayment agreement and a membership transfer agreement with Changzhou Xingkong Medical Beauty Clinic, involving a total debt of approximately RMB 215.5 million (around HKD 236 million) to be repaid in five installments from 2024 to 2028 [1] Group 1: Financial Performance - As of December 24, 2025, the stock price of China Regenerative Medicine closed at HKD 0.48, up 2.15% from the previous trading day, with a trading volume of HKD 6,978 [1] - The stock has seen a 52-week high of HKD 1.2 and a low of HKD 0.24 [1] Group 2: Debt Repayment Agreement - The company has entered into a debt repayment agreement with Changzhou Xingkong, confirming a total debt of RMB 215,498,644.46 (approximately HKD 236 million) owed by Changzhou Xingkong to the company's subsidiaries [1] - The repayment will occur in five interest-free installments from 2024 to 2028 [1] Group 3: Membership Transfer Agreement - A membership transfer agreement will be signed between HKIRC and Changzhou Xingkong along with 24 designated clients, transferring unused prepaid service fees valued at approximately RMB 45,121,000 to offset part of the debt [1] - As of the last feasible date, the outstanding debt amount is approximately RMB 108 million [1] Group 4: Compliance and Internal Measures - The transactions constitute major transactions but were not disclosed in a timely manner due to employee oversight, violating GEM listing rules [1] - The company has implemented internal training and strengthened internal controls as remedial measures and has obtained written approval from major shareholders, thus not convening a shareholders' meeting [1]
中国再生医学（08158.HK）披露有关结欠付款协议及会员转让协议之主要交易，12月24日股价上涨2.15%